Literature DB >> 21167718

Treatment of persistent and recurrent acromegaly.

Lana A Del Porto1, Simon V Liubinas, Andrew H Kaye.   

Abstract

Acromegaly is a chronic insidious disease characterised by growth hormone (GH) hypersecretion, typically from a pituitary adenoma. Effective treatment of acromegaly is vital because it is associated with a mortality rate more than twice that of the general population, an increased prevalence of colonic malignancy and many significant co-morbidities. Transsphenoidal adenoma resection is still the best first-line treatment for acromegaly but persistence (43%) or recurrence (2% to 3%) of GH hypersecretion after surgery remains a problem. Treatment options for acromegaly after failed initial therapy or recurrence include further surgery, radiotherapy, radiosurgery or medical therapies, including somatostatin analogues, dopamine agonists and growth hormone receptor antagonists. There has been a progressive lowering of the accepted GH level defining cure in acromegaly. This article reviews the efficacy and safety of the various treatment options for persistent or recurrent acromegaly and the changing definition of cure. Crown Copyright Â
© 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21167718     DOI: 10.1016/j.jocn.2010.10.003

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

1.  Gamma knife radiosurgery for clinically persistent acromegaly.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2012-04-26       Impact factor: 4.130

Review 2.  Current best practice in the management of patients after pituitary surgery.

Authors:  Alessandro Prete; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Ther Adv Endocrinol Metab       Date:  2017-03-01       Impact factor: 3.565

Review 3.  Management options for persistent postoperative acromegaly.

Authors:  Nestoras Mathioudakis; Roberto Salvatori
Journal:  Neurosurg Clin N Am       Date:  2012-08-09       Impact factor: 2.509

4.  Stepwise approach to myopathy in systemic disease.

Authors:  Jasvinder Chawla
Journal:  Front Neurol       Date:  2011-08-05       Impact factor: 4.003

5.  Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson's disease.

Authors:  Jacob S Daniel; Jyothish P Govindan; Chandan Kamath; Charles D'Souza; Mohamed A Adlan; Lakdasa D Premawardhana
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2014-05-01

Review 6.  Octreotide-Resistant Acromegaly: Challenges and Solutions.

Authors:  Giuliana Corica; Marco Ceraudo; Claudia Campana; Federica Nista; Francesco Cocchiara; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Diego Ferone; Federico Gatto
Journal:  Ther Clin Risk Manag       Date:  2020-05-05       Impact factor: 2.423

7.  Avoiding Complications in Endoscopic Trans-Sphenoidal Surgery for Pituitary Adenoma: A Beginner's Perspective.

Authors:  Pawan Goyal; Aditya Gupta; Sanjeev Srivastava; Shilpi Modi
Journal:  Asian J Neurosurg       Date:  2020-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.